Citation: | Lifang PANG, Yushen GU, Zhi YANG, Zhifang WU, Wei FAN, Xiaohua ZHU, Jun ZHAO, Changjiu ZHAO, Xuemei WANG, Yongju GAO, Li HUO, Yi MO, Meiyun WANG, Jie LU, Lingzhi HU, Zheng ZHANG, Feng WANG, Xuemei DU, Yue CHEN, Jianjun LIU, Zhaoping CHENG, Yunlong LOU, Shuzhan YAO, Rong XU, Sijin LI, Hongcheng SHI. 18F-FDG PET/MR Imaging for Evaluating of Obstructive Jaundice: Chinese Expert Consensus[J]. Clinical Cancer Bulletin, 2022, 1(2): 56-65. doi: 10.11910/j.issn.2791-3937.2022.20220014 |
All authors declare that they have no conflict of interest.
[1] |
Wang S. B., Wu H. B., Wang Q. S., et al. 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice. Hepatobiliary Pancreat Dis Int, 2015, 14(5): 516–522. doi: 10.1016/S1499-3872(15)60392-7
|
[2] |
Papadopoulos V., Filippou D., Manolis E., Mimidis K. Haemostasis impairment in patients with obstructive jaundice. J Gastrointestin Liver Dis, 2007, 6(2): 177–186.
|
[3] |
Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med, 1999, 341(18): 1368–1378. doi: 10.1056/NEJM199910283411807
|
[4] |
ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, et al. ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. Gastrointest Endosc, 2019, 89(6): 1075–1105. doi: 10.1016/j.gie.2018.10.001
|
[5] |
Modha K. Clinical Approach to Patients With Obstructive Jaundice. Tech Vasc Interv Radiol, 2015, 18(4): 197–200. doi: 10.1053/j.tvir.2015.07.002
|
[6] |
Chen CH, Tseng LJ, Yang CC, et al. Preoperative evaluation of periampullary tumors by endoscopic sonogrphy, transabdominal sonogrphy and computed tomography. J Clin Ultrasound, 2001, 29(6): 313–321. doi: 10.1002/jcu.1041
|
[7] |
Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut, 2012, 61(12): 1657–1669. doi: 10.1136/gutjnl-2011-301748
|
[8] |
Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver, 2017, 15;11(1): 13–26.
|
[9] |
Marion-Audibert AM, Vullierme MP, Ronot M, et al. Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. AJR Am J Roentgenol, 2018, 211(5): W1–W9.
|
[10] |
Hoeffel C, Azizi L, Lewin M, et al. Normal and pathologic features of the postoperative biliary tract at 3D MR eholangiopancre-atography and MR imaging. Radiographics, 2006, 26(6): 1603–1620. doi: 10.1148/rg.266055730
|
[11] |
Kim J Y, Kim M H, Lee T Y, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol, 2008, 103(5): 1145–1151. doi: 10.1111/j.1572-0241.2007.01710.x
|
[12] |
Ward RD, Amorim B, Li W, et al. Abdominal and pelvic 18F-FDG PET/MR: a review of current and emerging oncologic applications. Abdom Radiol(NY), 2021, 46(3): 1236–1248. doi: 10.1007/s00261-020-02766-2
|
[13] |
Guniganti P, Kierans AS. PET/MRI of the hepatobiliary system: Review of techniques and applications. Clin Imaging, 2021, 71(3): 160–169.
|
[14] |
Galgano SJ, Calderone CE, Xie C, et al. Applications of PET/MRI in Abdominopelvic Oncology. Radiographics, 2021, 41(6): 1750–1765. doi: 10.1148/rg.2021210035
|
[15] |
Ferrone C, Goyal L, Qadan M, et al. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1871–1884. doi: 10.1007/s00259-019-04558-3
|
[16] |
Ruys A. T, Kate F.J, Busch O.R, et al. Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford), 2011, 13(12): 881–886. doi: 10.1111/j.1477-2574.2011.00389.x
|
[17] |
Brix G, Nekolla EA, Nosske D, Griebel J. Risks and safety aspects related to PET/MR examinations. Eur J Nucl Med Mol Imaging, 2009, 36 Suppl 1: S131-S138.
|
[18] |
Tsai LL, Grant AK, Mortele KJ, Kung JW, Smith MP. A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. Radiographics, 2015, 35(6): 1722–1737. doi: 10.1148/rg.2015150108
|
[19] |
Shellock FG, Woods TO, Crues JV 3rd. MR labeling information for implants and devices: explanation of terminology. Radiology, 2009, 253(1): 26–30. doi: 10.1148/radiol.2531091030
|
[20] |
Galgano S, Viets Z, Fowler K, et al. Practical Considerations for Clinical PET/MR Imaging. PET Clin, 2018, 13(1): 97–112. doi: 10.1016/j.cpet.2017.09.002
|
[21] |
Chen S., Hu P., Fan W, et al. Expert consensus on PET/MR whole body imaging workflow and protocol planning. Chin J of Clin Med. 2020, 27(4): 713-721.
|
[22] |
Shi H. PET/CT clinical evidence-based practice and procedure guidance [M]. Shanghai Scientific & Technical Publishers, Shanghai, 2019.
|
[23] |
Gavra M, Syed R, Fraioli F, Afaq A, Bomanji J. PET/MRI in the Upper Abdomen. Semin Nucl Med, 2015, 45(4): 282–292. doi: 10.1053/j.semnuclmed.2015.03.002
|
[24] |
Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. Radiographics, 2006, 26(6): 1621–36. doi: 10.1148/rg.266065014
|
[25] |
Chen S, Hu P, Gu Y, et al. Impact of patient comfort on diagnostic image quality during PET/MR exam: A quantitative survey study for clinical workflow management. J Appl Clin Med Phys, 2019, 20(7): 184–192.
|
[26] |
Taouli B., Beer A. J, Chenevert T., et al. Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. J Magn Reson Imaging, 2016, 44(3): 521–540.
|
[27] |
Taouli B., Koh D. M. Diffusion-weighted MR imaging of the liver. Radiology, 2010, 254(1): 47–66. doi: 10.1148/radiol.09090021
|
[28] |
Hu P., Zhao J., Yang Z., et al. Expert consensus on standardization of PET/MR imaging examination of hepatobiliary system. Chin J of Clin Med. 2020, 27(5): 881-885.
|
[29] |
Chinese Society of Nuclear Medicine. 2020 Expert consensus for standardized report writing of PET/MR. Chin J Nucl Med Mol Imaging, 2020, 40(12): 743–746.
|
[30] |
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med, 2019, 60(6): 801–805. doi: 10.2967/jnumed.119.227967
|